10 research outputs found
Beneficial insulinsensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat
Recommendations from the European Bioanalysis Forum on method establishment for tissue homogenates
Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum
Impact of Compliance with Oral Antihyperglycemic Agents on Health Outcomes in Type 2 Diabetes Mellitus
Organic Anion Transporter 2鈥揗ediated Hepatic Uptake Contributes to the Clearance of High-Permeability鈥揕ow-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs
Formulation, Pharmacokinetics evaluation, and IVIVC Assessment of Gliclazide Multiparticulates in Rat Model
Applying the Taguchi Design for Optimized Formulation of Sustained Release Gliclazide Chitosan Beads: An In Vitro/In Vivo Study
Gliclazide is a second generation of hypoglycemic sulfonylurea and acts selectively on pancreatic 尾 cell to control diabetes mellitus. The objective of this study was to produce a controlled release system of gliclazide using chitosan beads. Chitosan beads were produced by dispersion technique using tripolyphosphate (TPP) as gelating agent. The effects of process variables including chitosan molecular weight, concentration of chitosan and TPP, pH of TPP, and cross-linking time after addition of chitosan were evaluated by Taguchi design on the rate of drug release, mean release time (MRT), release efficiency (RE8%), and particle size of the beads. The blood glucose lowering effect of the beads was studied in normal and streptozotocin-diabetic rats. The optimized formulation CL2T5P2t10 with about 31% drug loading, 2.4聽h MRT, and 69.16% RE8% decreased blood glucose level in normal rats for 24聽h compared to pure powder of gliclazide that lasted for just 10聽h